Guideline adherence for the systemic treatment of (metastatic) colorectal cancer was surveyed among oncologists in The Netherlands. Reported overtreatment patterns (adjuvant setting) and undertreatment patterns for targeted therapies (metastatic setting) were identified, possibly explained by unawareness or disagreement with the guidelines, or local financial restrictions. Additional support for guideline implementation and monitoring besides investigating underlying causes for nonadherence is recommended. Background: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over-and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. Patients and Methods: In all Dutch hospitals (n ¼ 88) 1 medical oncologist involved in colorectal cancer care was approached to participate. An online survey was conducted regarding the local standard of care for adjuvant chemotherapy in high-risk stage II and stage III colon cancer and first-line treatment regimens in metastatic colorectal cancer. Frequency tables were provided for categorical variables and compared for differences in guideline adherence according to hospital type (academic/teaching/regional). Results: The overall response rate was 70% (62 of 88). Reported guideline adherence was at least 60% of all presented settings. For high-risk stage II and stage III colon cancer, treatment strategies agreed with national guidelines in 66% and 84% of hospitals, and overtreatment patterns were identified in 28% and 13%, respectively. Targeted therapy was not routinely administered as first-line treatment in metastatic colorectal cancer (range from 63% to 71% in different settings). No differences in guideline adherence were observed among different hospital types. Conclusion: Guideline adherence as reported by medical oncologists in The Netherlands is suboptimal. Possible explanations include unawareness or disagreement with the guidelines, or local financial restrictions. Our results recommend additional support of guideline implementation and monitoring in clinical practice, and investigating underlying causes in case of nonadherence.
Introduction
Clinical practice guidelines are generated to improve high-quality evidence-based care of patients and to prevent undesirable practice variation. In The Netherlands, a team of medical experts of all relevant specialties is responsible for updating the guideline recommendations every few years on the basis of recent literature or consensus if no evidence-based data exist. The national guideline serves as a basis for clinical practice, but it is known that hospitals in The Netherlands might differ in their interpretation of the guidelines.
In 2014, a new Dutch guideline for colorectal cancer was published, which included updated recommendations for adjuvant chemotherapy for high-risk stage II and stage III colon cancer and systemic treatment for metastatic colorectal disease. 1 In patients with early stage (I and II) colon cancer, the use of adjuvant chemotherapy has been restricted, which implies that fewer patients should be exposed to the morbidity (and sometimes mortality) that is associated with this treatment. 2 In the metastatic setting, treatment options have been expanded by the incorporation of novel targeted drugs in treatment regimens, leading to improved survival. 2 There are no significant differences between Dutch guideline recommendations and international European Society for Medical Oncology (ESMO) 3, 4 and National Comprehensive Cancer Network (NCCN) guidelines. 5 American Society of Clinical
Oncology colorectal cancer guidelines for systemic therapy are lacking, except for an outdated (2004) guideline regarding adjuvant chemotherapy for stage II colon cancer. 6 Guideline adherence for adjuvant treatment strategies in colorectal cancer has been investigated earlier. [7] [8] [9] [10] In The Netherlands a suboptimal adherence during 2001 to 2007 was observed, 7 despite that the survival benefit of adjuvant chemotherapy had been demonstrated. 11 For metastatic colorectal cancer, the current guideline provides clear recommendations for the use of antivascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) agents, but the use of these drugs in several Dutch hospitals is restricted, at least partly because of the high costs of these drugs. However, data on this topic are scarce. Recent studies showed that bevacizumab was not administered in 41% to 49% of Dutch patients as part of first-line treatment for metastatic colorectal cancer. 12, 13 Therefore, the aim of our provider-based study was to compare the reported use of adjuvant and metastatic colorectal treatment regimens with the recommendations in the most recent Dutch colorectal cancer guideline.
Methods

Study Population
We conducted an online questionnaire on the local implementation of the most recent Dutch colorectal cancer guideline recommendations for the use of systemic treatment in high-risk stage II and stage III colon cancer and in first-line for metastatic colorectal cancer outside the context of clinical trials (see Supplemental Appendix 1 in the online version. In the beginning of 2016 we invited 1 medical oncologist involved in colorectal cancer care in each of all 88 Dutch hospitals to participate. We sent 2 online reminders after initial invitation and 1 by regular mail.
Adjuvant Chemotherapy According to the 2014 Dutch Guidelines
Adjuvant chemotherapy after curative resection has been the standard recommended treatment for stage III colon cancer, with fluoropyrimidine (5-fluorouracil or capecitabine) with oxaliplatin being the most effective regimen. 11, 14 In the most recent 2014 
Outcomes
The survey consisted of 16 questions with 2 general questions on hospital type and time since registration as medical oncologist. Hospital type was classified as academic hospital/cancer institute, teaching hospital, or regional hospital. The subsequent 14 questions concerned the use of adjuvant chemotherapy (9 questions) and systemic treatment regimens for metastatic colorectal cancer (5 questions). More specifically, the survey included questions concerning age limits (2 questions), timing of adjuvant chemotherapy in relation to surgery (1 question), ambulant or clinical continuous infusion of 5-fluorouracil (1 question), adjuvant chemotherapy for rectal cancer (1 question), and chemotherapy after surgical resection of colorectal liver metastases (1 question).
Three questions focused on the use of adjuvant chemotherapy in high-risk stage II and stage III colon cancer in relation to microsatellite status and possible contraindications for oxaliplatin. In total, 8 clinical situations were presented and the responses were compared with the 2014 Dutch guideline recommendations. Reported guideline adherence was defined as adherence in accordance to the Dutch 2014 guidelines and was calculated per case and overall per stage (high-risk stage II and stage III). Nonadherence could imply overtreatment as well as undertreatment. Overtreatment was defined as the use of systemic therapy without a justified indication (eg, adjuvant chemotherapy for patients with high-risk stage II MSI tumors) and undertreatment as the nonuse of systemic therapy although this was indicated (eg, no adjuvant chemotherapy for patients with stage III MSS tumors) or the use of fluoropyrimidine monochemotherapy although doublet chemotherapy was indicated (eg, capecitabine monotherapy for patients with stage III MSS tumors without contraindications for oxaliplatin).
Another 4 questions concerned the use of first-line systemic treatment regimens with curative or palliative intent in metastatic colorectal cancer, both in relation to the RAS mutation status of the tumor. The last question concerned the use of expensive drugs in relation to financial aspects.
Statistical Analysis
The online questionnaire was conducted using LimeSurvey Software, 17 which produced data without identifying variables. We analyzed our data using SPSS Statistics version 23 (IBM Corp). We provided frequency tables with percentages for categorical variables for high-risk stage II and stage III colon cancer treatment regimens and metastatic colorectal disease. Subsequently we made a top 10 ranking of first-line preferred regimens for metastatic colorectal disease. Fisher exact tests were performed to compare differences in guideline adherence according to hospital type.
Results
The overall response rate of the survey was 70% (62 of 88). Responding medical oncologists had a median experience of 13 years in oncology since their registration. Of the responders, 7 (11%) were working in an academic hospital or oncological center, 22 (36%) in a teaching hospital, and 32 (53%) in a regional hospital. One responder was excluded in the analysis, because only 1 question was answered. Three responders had only answered questions about adjuvant chemotherapy regimens and not metastatic disease and were only included in the adjuvant treatment analysis.
Adjuvant Chemotherapy
Upper Limit of Age. In the Dutch guidelines no age limit is recommended, but the added value of oxaliplatin in elderly people (age older than 70 years) is mentioned as unclear. Only 1 responder (1 of 61; 2%) reported an age limit (80 years) for the use of adjuvant chemotherapy in general. For the use of oxaliplatin, 26% (n ¼ 16) reported an age limit: 70 years (n ¼ 10), 75 years (n ¼ 4), and 80 years (n ¼ 2).
Timing in Relation to Surgery. According to the Dutch guidelines, adjuvant chemotherapy is preferably started within 8 weeks after surgery, but not later than 12 weeks after surgery. Timing of chemotherapy was reported for 51 responders (84%) with a range between surgery and the start of adjuvant chemotherapy of 3 to 13 weeks (median: 10 weeks). The remaining 10 responders (16%) did not report a maximum interval between surgery and the start of adjuvant chemotherapy.
Adjuvant Chemotherapy for Rectal Cancer. The Dutch guidelines do not recommend adjuvant chemotherapy for rectal cancer. Adjuvant chemotherapy for rectal cancer is considered by 7% of responders (n ¼ 4) with always a fluoropyrimidine with oxaliplatin as the preferred regimen.
Adjuvant Chemotherapy After Resection of (Liver) Metastases. The Dutch guidelines do not recommend adjuvant chemotherapy after resection of (liver) metastases. In total, 33% of responders (n ¼ 20) reported the use of fluoropyrimidines with oxaliplatin sometimes combined with bevacizumab as adjuvant treatment regimen after resection of (liver) metastases.
High-Risk Stage II and Stage III Colon Cancer
High-Risk Stage II. For patients with high-risk stage II tumors, only oxaliplatin-based adjuvant chemotherapy is recommended, provided that the tumor is MSS. Of the responders, 97% considered adjuvant chemotherapy in case of high-risk stage II colon cancer (59 of 61). For MSS tumors, guideline adherence was 84% for patients without a contraindication for oxaliplatin and 33% for patients with a contraindication for oxaliplatin. For MSI tumors, guideline adherence was 61% and 87%, respectively. The average guideline adherence was 66%. Of 61 responders, 13 (21%) answered all 4 cases in accordance with the Dutch guideline. On average overtreatment was reported in 28% and undertreatment in 3% for high-risk stage II treatment regimens compared with the Dutch guideline.
Stage III. For patients with stage III tumors, fluoropyrimidine with oxaliplatin is the standard recommended treatment. Fluoropyrimidine monotherapy may be considered in stage III patients not eligible for oxaliplatin treatment, provided that the tumor is MSS. For MSS tumors, guideline adherence was 97% for patients without a contraindication for oxaliplatin use and 90% for patients with a contraindication for oxaliplatin use. For MSI tumors, guideline adherence was 97% and 51%, respectively. The average guideline adherence was 84%. Of 61 responders, 32 (52%) answered all 4 cases in accordance with the Dutch guideline. Overtreatment was reported in 13% and undertreatment in 0% for stage III treatment regimens compared with the Dutch guideline. Figure 1B shows a summary of adherence, overtreatment, and undertreatment patterns for the different presented clinical situations.
Guideline Adherence in CRC Treatment in The Netherlands
Figure 1A shows the results of adjuvant chemotherapy regimens for high-risk stage II and stage III colon cancer. Treatment regimens as recommended in the Dutch guidelines are marked with an asterisk.
First-Line Systemic Treatment of Metastatic Colorectal Cancer With Palliative Intent
For patients with permanently unresectable metastases, a fluoropyrimidine-containing schedule (monotherapy or combination with irinotecan or oxaliplatin) in combination with bevacizumab is recommended as the standard of care. For first-line palliative treatment in patients with RAS wild type tumors, 63% of the responders always administer bevacizumab during first-line palliative treatment and 37% do not (28% sometimes; 9% never). Of the responders who never used bevacizumab, 20% were from teaching hospitals and 80% from regional hospitals. For patients with RAS mutated tumors, the use of bevacizumab was reported as follows: always (66%) versus not routinely 34% (27% sometimes and 7% never). No differences in bevacizumab prescription were found between responders from different types of hospitals. For targeted therapy in general (bevacizumab, panitumumab, and cetuximab), 64% of the responders always administer targeted therapy to patients with RAS wild type tumors (29% sometimes, 7% never) compared with 66% (always) and 34% (27% sometimes; 7% never) of responders who administer targeted therapy to patients with RAS mutated tumors. A top 10 ranking of reported first-line preferred treatment regimens for permanently unresectable metastatic colorectal cancer with RAS wild type and RAS mutated tumors is shown in Figure 2 .
First-Line Systemic Treatment of Metastatic Colorectal Cancer With Curative Intent
Patients with initially unresectable but potentially resectable metastases of RAS wild type tumors are to be treated with doublet or even triplet chemotherapy in combination with bevacizumab or EGFR antibodies. In our survey, responders always administer targeted therapy in 71% versus 29% who do not routinely administer targeted therapy (20% sometimes; 9% never). This 9% concerns 4 responders from a regional and 1 from an academic hospital. The use of targeted therapy in patients with RAS mutated 
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Clinical Colorectal Cancer March 2018 -61 tumors is as follows: always-70%-vs. not routinely-19% sometimes; 11% never. No differences in targeted therapy administration were observed between responders from different types of hospitals. In Figure 3 , a top 10 ranking of reported first-line preferred treatment regimens for induction therapy is presented. Doublet chemotherapy in the first-line setting is provided to 91% of patients with RAS wild type and 89% of patients with RAS mutated tumors. Five responders (9%) do not routinely administer targeted therapy. Four of these responders reported insufficient evidence about the clinical benefits of targeted therapy as their motivation.
Discussion
We conducted a nationwide provider survey evaluating reported adherence to the most recent Dutch colorectal cancer guideline using an online questionnaire. The overall adherence to the guidelines was more than 60% in the settings that were presented. However, our survey showed suboptimal reported adherence to the guideline recommendations for adjuvant treatment regimens in high-risk stage II and stage III colon cancer, and for first-line treatment regimens in metastatic colorectal disease. Reported nonadherence to the national guidelines was 34% and 16% for 
Guideline Adherence in CRC Treatment in The Netherlands
high-risk stage II and stage III colon cancer, respectively, which mostly concerned overtreatment patterns for adjuvant treatment policy (28% in high-risk stage II, 13% in stage III). For metastatic colorectal cancer, reported first-line systemic treatment regimens differed from the Dutch guideline during palliative and curative settings in 37% and 34% (RAS wild type and RAS mutated) and 29% and 30% (RAS wild type and RAS mutated) of cases, respectively. Several explanations can be considered for nonadherence to the guidelines in clinical practice. In the adjuvant setting, medical oncologists might have been unaware of or disagreed with the adjusted guideline recommendations in 2014, which could lead to overtreatment and undertreatment. One of our findings is the reported administration of fluoropyrimidine monotherapy to patients with high-risk stage II (MSS tumor) and stage III (MSI tumor) colon cancer contraindicated to oxaliplatin, whereas the Dutch guideline recommends against the use of fluoropyrimidine monotherapy in these cases. Guideline adherence concerned 33% and 51% in these situations, respectively. We can only speculate about the reasons for nonadherence, but medical oncologists might feel uncomfortable withholding any adjuvant chemotherapy in these patients. Furthermore, the ESMO guidelines are less explicit concerning nonadministration of adjuvant chemotherapy for these patient categories compared with the Dutch guidelines. However, in case of metastatic disease, local restrictions to the health care budget could be an alternative or additional reason. In The Netherlands, each hospital annually negotiates their health care budget in advance with health care insurance providers regarding so-called 'expensive drugs' (eg, bevacizumab and anti-EGFR therapy), but this does not guarentee enough budget for every patient that qualifies during the year. Therefore, hospitals have local restrictions or possibly local guidelines for the administration of expensive drugs, but we were unable to show this with our results.
We show that only 9% of responders did not routinely administer targeted therapies according to the guidelines, whereas the same responders reported that targeted therapy adherence rates were low. This might be caused by a social desirability bias when asked for reasons for nonprescription of targeted therapies, despite emphasizing anonymous participation in our survey. Further research in which we will compare the results of our survey with daily practice populationbased data from the independent Dutch Cancer Registry is ongoing. Financial restrictions were not reported by any responder, but this 9% does not explain overall nonadherence. Cost-effectiveness of bevacizumab and anti-EGFR therapy has been evaluated, with minimal incremental benefit at high incremental costs per qualityadjusted life year. 18, 19 Therefore, financial restrictions are a likely cause of nonadministration with debatable cost-effectiveness in combination with an insufficient health care budget. We focused on guideline adherence in The Netherlands according to Dutch guideline recommendations. These largely correspond with international guidelines for systemic therapy for colorectal cancer, but subtle differences in international guideline recommendations compared with the Dutch guidelines exist. The ESMO guidelines are less specific regarding the indication for adjuvant chemotherapy in high-risk stage II patients with MSI tumors, and state that any benefit of chemotherapy is unlikely, but do not explicitly recommend to withhold adjuvant chemotherapy in this patient population. The same applies to the use of fluoropyrimidine monotherapy in stage III patients with MSI tumors. The ESMO guidelines mention the existence of conflicting data on the benefit of treatment of fluoropyrimidine monotherapy, but do not explicitly advise against the use of monotherapy. In the metastatic palliative setting, the ESMO guidelines recommend doublet chemotherapy with bevacizumab or (in patients with RAS wild type tumors) EGFR antibodies, 5-fluorouracil with oxaliplatin and irinotecan with or without bevacizumab (in patients with BRAF mutated tumors) and fluoropyrimidines with bevacizumab or best supportive care for unfit patients. The NCCN guidelines do not recommend a certain type or targeted therapy for first-line regimens whereas the Dutch guideline recommends fluoropyrimidine-based chemotherapy combined with bevacizumab in the first-line setting. However, when we apply ESMO as well as NCCN guideline recommendations to the results of our survey for first-line systemic therapy (ie, all fluoropyrimidine-based chemotherapy in combination with targeted therapy), reported guideline adherence still remains suboptimal (64% for RAS wild type and 66% for RAS mutated tumors).
To our knowledge, this is the first provider-based survey to evaluate adjuvant and metastatic treatment regimens for colorectal cancer. The high response rate of 70% to our survey from medical oncologists of different types of hospitals suggests that our results might reflect clinical practice in The Netherlands. However, because no information of nonresponders is available, our results might still overestimate or underestimate guideline adherence. A possible limitation of our survey is that we approached 1 medical oncologist per Dutch hospital. However, we are aware that guideline adherence might differ among medical oncologists from the same department. We selected medical oncologists who were known to be the local investigator for national multicenter clinical studies on colorectal cancer and should therefore be considered to represent the treatment policy in colorectal cancer of that particular center. We selected a pragmatic approach to obtain well balanced national results and we attempted to include the medical oncologist who was known to be most involved in colorectal cancer patient care.
Furthermore, although our survey was anonymously processed and analyzed, socially desirable answers might have been possible, which could have underestimated the rate of nonadherence. Ideally, guideline adherence is evaluated objectively with actual patientbased data. In The Netherlands, a national registration of colorectal cancer patients is in progress 20 and might be scrutinized on this topic in the near future. Last, our results might not be representative for other countries. Although guidelines with comparable content are available in other Western countries 3,4 variation in guidelines 21 as well as differences in treatment reimbursement might differ among countries, which does not allow generalization of our findings. However, our results certainly justify further research on guideline adherence for other types of cancer and investigations outside The Netherlands.
Conclusion
We observed reported nonadherence to the national guidelines which could lead to practice variation in the treatment of colorectal cancer patients in The Netherlands. This nonadherence predominantly concerned reported overtreatment of adjuvant chemotherapy regiments in high-risk stage II and stage III colon cancer and
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Clinical Colorectal Cancer March 2018 -63 reported undertreatment with targeted therapy of patients with metastatic colorectal cancer. Our data warrant further investigations on the underlying causes of this nonadherence. Unawareness of the most recent guidelines should require a strategy for a more optimal implementation of guidelines into clinical practice, disagreement with current guidelines should require a better strategy for guideline preparation, and budget restrictions to the implementation of guidelines should call for negotiations with health care providers. In any case, the results of our survey clearly show that the existence of guidelines does not guarantee an optimal adherence and thereby the quality of care in clinical practice.
Clinical Practice Points
Clinical guidelines are generated to preserve high-quality evidence-based care, but data on the implementation of guidelines into clinical practice are scarce. We conducted a survey regarding the local standard of care for the systemic treatment of colorectal cancer patients among medical oncologists in Dutch hospitals (n ¼ 88). In the adjuvant setting, the average reported guideline adherence was 66% for patients with high-risk stage II and 84% for patients with stage III colon cancer. We identified reported overtreatment patterns with fluoropyrimidine monotherapy for patients contraindicated for oxaliplatin treatment with high-risk stage II (MSS tumor) and stage III (MSI tumor) colon cancer. In the metastatic palliative setting, bevacizumab was routinely administered in 63% (RAS wild type) and 66% (RAS mutated) of patients, whereas in the metastatic curative setting targeted therapies were routinely administered in 71% (RAS wildtype) and 70% (RAS mutated) of patients. No differences in reported guideline adherence were observed among different hospital types (academic, teaching, regional). Possible explanations for guideline nonadherence include unawareness or disagreement with the guidelines, or local financial restrictions. Our results recommend additional support of guideline implementation and monitoring in clinical practice, and investigating underlying causes in case of nonadherence.
